Perlegen Defunct: PGx Firm Shutters Doors After R&D Disappointments, Mounting Losses

A review of the privately held pharmacogenomics company's activities from when it opened its doors in 2000 to just before it shuttered in late 2009 suggests that despite partnerships with academia and big pharma, opportunistic R&D investments in key markets, and at least one recently launched commercial diagnostic product, the company was unable to remain solvent. R&D disappointments, losses related to a government contract, and the economic crisis may have directly forced the company to close.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.

Related Stories